Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

Cathrine Axfors1,2, Perrine Janiaud3†, Andreas M. Schmitt3,4, Janneke van’t Hoof6, Emily R. Smith6, Noah A. Haber1, Akin Abayomi7, Manal Abduljalil8, Abdulkarim Abdulrahman9,10, Yeny Acosta-Ampudia11, Manuela Aguilar-Guisado12, Farah Al-Beidh29, Lynn B. Bonifacio15, Asha C. Bowen30,31,32, Abbie Bown33, Carlos Cabello-Gutierrez34, Bernardo Camacho35, Adrian Camacho-Ortiz36, Sally Campbell-Lee37, Damon H. Ca9, Ana Cardesa39, Jose M. Carnate40, German Jr. J. Castillo15, Rossana Cavallo41, Fazle R. Chowdhury42, Forhad U. H. Chowdhury43, Giovannino Ciccone44, Antonella Cingolani45, Fresthel Monica M. Climacosa46, Veerle Compernolle47, Carlo Francisco N. Cortez15, Abel Costa Neto49, Sergio D’Antico50, James Daly51, Franca Danielle52, Joshua S. Davis30, Francesco Giuseppe De Rosa53, Justin T. Denholm54,55, Claudia M. Denkinger56, Daniel Desmecht57, Juan C. Diaz-Coronado58, Juan A. Diaz Ponce-Medrano59, Anne-Francoise Donneau60, Teresita E. Dumagay15, Susanna Dunachie16, Cecile C. Dunog40, Olufemi Erinoso61, Ivy Mae S. Escasa15, Lise J. Estcourt62,63, Amy Evans64, Agnes L. M. Evasan14, Christian J. Farell65, Veronica Fernandez-Sanchez66, Claudia Galassi44, Juan E. Gallo67, Patricia J. Garcia68, Patricia L. Garcia69, Jesus A. Garcia70, Mutien Garigliany57, Elvira Garza-Gonzalez36, Deonne Thaddeus V. Gauiran15, Paula A. Gaviria Garcia35, Jose-Antonio Giron-Gonzalez71, David Gómez-Almaguer72, Anthony C. Gordon13,73, André Gothot74, Jeser Santiago Grass Guaqueta35, Cameron Green75, David Grimaldi76, Naomi E. Hammond77, Heli Harvala78, Francisco M. Heralde79, Jessica Herrick80, Alisa M. Higgins75, Thomas E. Hills81,82, Jennifer Hines83, Karin Holm84,85, Ashraful Hoque86, Eric Hoste87, Jose M. Ignacio88, Alexander V. Ivanov89, Maike Janssen90, Jeffrey H. Jennings83, Vivekanand Jha81,92,93, Ruby Anne N. King79, Jens Kjeldsen-Kragh94, Paul Klennerman16, Aditya Kotecha83, Fiorella Krapp95, Luciana Labanca52, Emma Laing64, Mona Landin-Olsson96,97, Pierre-François Laterre98, Lynn-Li Lim99, Jodor Lim14, Oskar Ljungquist100, Jorge M. Llaca-Diaz101, Concepción López-Robles102,

†Correspondence: lars.hemkens@usb.ch

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Abstract

Background: Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials (Open Science Framework, https://doi.org/10.17605/OSF.IO/GEHFX).

Methods: In this collaborative systematic review and meta-analysis, clinical trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform), the Cochrane COVID-19 register, the LOVE database, and PubMed were searched until April 8, 2021. Investigators of trials registered by March 1, 2021, without published results were contacted via email. Eligible were ongoing, discontinued and completed randomized clinical trials that compared convalescent plasma with placebo or no treatment in COVID-19 patients, regardless of setting or treatment schedule. Aggregated mortality data were extracted from publications or provided by investigators of unpublished trials and combined using the Hartung–Knapp–Sidik–Jonkman random effects model. We investigated the contribution of unpublished trials to the overall evidence.

Results: A total of 16,477 patients were included in 33 trials (20 unpublished with 3190 patients, 13 published with 13,287 patients). 32 trials enrolled only hospitalized patients (including 3 with only intensive care unit patients). Risk of bias was low for 29/33 trials. Of 8495 patients who received convalescent plasma, 1997 died (23%), and of 7982 control patients, 1952 died (24%). The combined risk ratio for all-cause mortality was 0.97 (95% confidence interval: 0.92; 1.02) with between-study heterogeneity not beyond chance ($I^2 = 0\%$). The RECOVERY trial had 69.8% and the unpublished evidence 25.3% of the weight in the meta-analysis.

Conclusions: Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care.

Keywords: Meta-analysis, SARS-CoV-2, COVID-19, Convalescent plasma
Introduction
The transfer of plasma from a patient who recovered and is convalescent from coronavirus disease 2019 (COVID-19) to a person currently suffering from the disease aims to create transient passive immunity to combat the active infection. Convalescent plasma treatment has previously been used to treat, e.g., SARS-CoV-1, MERS, and H1N1 influenza [1–4]. Non-randomized studies indicated a beneficial effect on mortality in COVID-19 [5]. However, as stated by the US Food and Drug Administration (FDA) in March, 2020, “although promising, convalescent plasma has not been shown to be effective in every disease studied” [6]. Thousands of patients with COVID-19 worldwide have received convalescent plasma outside of clinical trials. In the US, this has occurred under single-patient emergency investigational new drug authority, as well as the National Expanded Access Protocol [7, 8] and an Emergency Use Authorization (EUA) by the FDA on August 23, 2020 [9]. No authorization has been issued by the European Medicines Agency; however, the European Commission developed guidance for monitored use [10] together with the European Centre for Disease Prevention and Control and the European Blood Alliance, and announced in January 2021 to allocate grants of €36 million to expand plasma collection programs [11].

When the results of the largest convalescent plasma trial enrolling more than 11,000 participants, the Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, were published as press release in January 2021, four randomized trials on convalescent plasma had been published in peer-reviewed journals [12–15] and five had been reported in preprints [16–20]. No trial had reported mortality benefits of a convalescent plasma treatment [21]. Subsequently, several other trials have closed their recruitment according to registry entries.

To summarize all available data on mortality effects of convalescent plasma for COVID-19, we conducted a collaborative systematic review and meta-analysis of all published and unpublished randomized clinical trials that are ongoing, discontinued or completed, investigating the effects of convalescent plasma treatment in patients with COVID-19 compared to placebo or no intervention.

Methods
The study protocol was posted at the Open Science Framework before data collection [22] and not in a review registry. We report the study under consideration of the PRISMA 2020 statement [23].

Data sources and searches
We identified all eligible trials from ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform [ICTRP] as of September 28, 2020, through the COVID-evidence database. We also searched PubMed, the Cochrane COVID-19 trial registry and the LOVE database [24] for published results (preprints and peer-reviewed journals) as of April 8, 2021 using search strategies with terms related to convalescent plasma and COVID-19 with a standard randomized clinical trials filter (Additional file 1).

Collaborative approach
For all unpublished and/or ongoing trials identified in the initial search as of September 28, 2020, and during an update by March 1, 2021, trial investigators were invited to provide their data and collaborate (Additional file 2). Investigators were also asked to provide additional details regarding the randomization and allocation concealment procedures for their trial.

Study selection
We included all trials that reported randomly allocating patients with confirmed or suspected Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection to a treatment with convalescent plasma versus placebo or no additional treatment other than the usual local care. We considered all trials that randomized at least one patient in the experimental arm and one patient in the control arm, regardless of the treatment regime for convalescent plasma or standard of care, as long as there were no differences in the treatments used in the arms beyond the convalescent plasma treatment or placebo. Trials could report all-cause mortality at any time point regardless of whether it was the primary outcome or not. We did not put any restrictions on trial status, language, geographical region, or healthcare setting. One reviewer (CA or PJ) screened each record for inclusion and potential duplicates of trials. Deduplication was conducted in R version 3.6.2 (R Foundation for Statistical Computing).

Data extraction and risk of bias assessment
We extracted the following trial characteristics based on the trial registry record or the publication (where available): descriptions of experimental and control arms, patient setting, eligibility criteria for recipients and donors, study location, blinding, target sample size, trial status. We contacted investigator teams of all trials without published results (Additional file 2) and requested aggregated, trial-level mortality data and confirmation of the descriptive characteristics that we extracted. Each data point was thus collected by two reviewers (CA/PJ and collaborating trial investigators). If several follow-up points were available, we chose the longest. For each treatment arm in a trial, we collected the number of deceased patients and the number of randomized patients (intention-to-treat data). We also collected

Axfors et al. BMC Infectious Diseases  (2021) 21:1170
information on the number of patients without available mortality data (lost to follow-up). Finally, for potentially eligible trials that were not included, we extracted the current recruitment status as of March 1, 2021 from trial registries and asked investigators for confirmation of the status and current accrual.

Two reviewers (CA and PJ) independently assessed the risk of bias of included RCTs using the Cochrane risk of bias tool 2.0 [25]. Disagreements were resolved through discussion. The assessment was done using information reported in the preprints and journal publications or provided by investigators for unpublished trials. Small-study effects were assessed using a funnel plot and Egger’s test. The presence of small-study effects may be suggestive, but not definitive, of publication bias [26].

**Data synthesis and analysis**

We prespecified all-cause mortality as our sole outcome. We report absolute numbers, proportions, and treatment effect estimates (risk ratio, RR) with 95% confidence interval (CI). A meta-analysis was performed to combine RRs across all trials using the Hartung-Knapp-Sidik-Jonkman (HKSJ) random-effects model [27] with Paule and Mandel (PM) tau-squared estimator, correcting for zero events in one study arm by adding the reciprocal of the size of the contrasting arm [28]. We expected a large variation in sample size and in the number of outcome events across trials, with a proportion of trials presenting with zero events in one or both arms and therefore the HKSJ-PM method would perform well in terms of equality of weights between trials. Statistical heterogeneity is described with the I²-statistic [29]. In 3 multi-arm studies, we considered each eligible comparison separately in the main analysis as prespecified; we also added a sensitivity analysis combining them. A RR < 1 means treatment with convalescent plasma reduced overall mortality.

We conducted sensitivity analyses to assess robustness across meta-analytic approaches using the DerSimonian–Laird and Sidik–Jonkman tau-squared estimators, Mantel–Haenszel random-effects method, Peto’s odds ratio method and profile likelihood method. We also repeated all meta-analytic approaches using the arcsine difference, a variant to the handling of zero events. DerSimonian–Laird is a standard random-effects meta-analysis approach but underestimates uncertainty. The Sidik–Jonkman tau-squared estimator, on the other hand, may yield inflated estimates if heterogeneity is low [30]. The Mantel–Haenszel method performs reasonably well with small and zero event counts, similar to Peto’s odds ratio method or with the arcsine transformation for zero events. The Peto’s odds ratio method is, however, suboptimal in the presence of substantial imbalances in the allocation of patients randomized in the compared arms.

In exploratory subgroup analyses, we stratified trials by (1) publication status (results published in peer-reviewed publications and preprints versus unpublished); (2) patient setting (ICU patients; inpatients with oxygen supplementation; inpatients with or without oxygen supplementation); and (3) antibody titer level (confirmed high-titer versus low-titer or unconfirmed titer). We defined high-titer as S-protein receptor binding domain (RBD)-specific IgG antibody titer of ≥1640 or higher, or serum neutralization titer of ≥1:40 or higher [14]. For studies using the Ortho VITROS SARS-CoV-2 IgG test, which reports a signal-to-cutoff (S/C) value, we defined high titer as S/C≥12 (corresponding to the initial US emergency use authorization) as prespecified. We complemented the high-titer definition with additional information made available in the March 2021 version emergency use authorization [31] (e.g., EUROMMUN (ratio ≥ 3.5) and Abbott ARCHITECT (S/C ≥ 4.5). We furthermore stratified trials by (4) control type (placebo versus no treatment); (5) timing of treatment (maximum 14 days after symptom onset versus not maximum 14 days after symptom onset); (6) donor pregnancy history (only using donated plasma from men, nulliparous women, or women testing negative for human leukocyte antigen (HLA) antibodies, versus including non-nulliparous women without HLA antibody testing); and (7) donor severity of COVID-19 (moderate or severe disease [e.g., whose infection required hospitalization] versus mild disease) [1, 32]. We added a non-prespecified subgroup analysis stratified by region, pooling high-income countries (Australia, Bahrain, Belgium, Chile, Germany, Italy, Netherlands, New Zealand, Spain, Sweden, United Kingdom, USA) versus middle-income countries (Argentina, Bangladesh, Brazil, China, Colombia, India, Iran, Mexico, Nigeria, Peru, Philippines, Russia) [33]. We also added a non-prespecified subgroup analysis separating trials with early administration of high-titer plasma in hospitalized patients from other trials, given the updated emergency use authorization by the FDA in February 2021 [34] The non-prespecified analyses are further described in Additional file 3; there were no substantial deviations from the protocol. For the subgroup analysis on donor pregnancy status (“Excluding potentially HLA antibody positive persons”) we used the non-prespecified Hartung–Knapp “ad hoc” variance correction [35] (this group included only two very small studies with large imprecision which can provide abnormally anticonservative estimates [36]).

We describe the accumulation of publicly available evidence in a cumulative non-prespecified meta-analysis using the HKSJ random-effects model with PM tau-squared, with published trials ordered by their date of publication or preprint posting, and the unpublished
trials added to the model last as one summarized treatment estimate.

We used R version 3.6.2 (the ‘meta’ and ‘metaplus’ packages) for the analyses (R Foundation for Statistical Computing).

Patient involvement statement
No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for design or implementation of the study. No patients were asked to advise on interpretation or writing up of the results. All-cause mortality is selected as an important outcome in COVID-19 research by Core Outcome Set developers that involved patients as a key stakeholder group [37].

Results
Of 4005 unique records identified in trial registries, literature databases, and other repositories, 102 trials were potentially eligible based on the information available (Fig. 1 and Additional file 4). We identified and included 7 already published trials (4 preprints [17–19, 38] and 3 publications) [13–15] at the time of our initial search (September 28, 2020) or at an update (March 1, 2021). In addition, investigators of 90 unpublished trials with a valid email address were contacted, 51 teams responded, 5 trials were confirmed ineligible, and investigators of 26 eligible trials shared their data. Of these, 20 trials are still unpublished, and 5 have been posted as preprints [16, 20, 39] or published in peer-reviewed journals [12, 40] as of April 8, 2021. Since then, the RECOVERY Trial has been published in a peer-review journal [41] and the IRCT20200310046736N trial has been published [42]; resulting in 13 published trials (6 preprints and 7 publications) and 20 unpublished trials included.

We included 33 trials with 16,477 participants (median 66, interquartile range IQR 31 to 120, range 5 to 11,558) (Table 1). Fourteen of these 33 trials were ongoing (42%). Without taking into account the adaptive trials whose final sample size is not fixed (ASCOT, REMAP-CAP and the RECOVERY Trial), 5552 patients were planned to be enrolled in the remaining 30 trials of which 52% (2872/5552) have been included in the meta-analysis. The 33 trials were conducted in Europe (n=12), Asia (n=8), South America (n=7), North America (n=3), Africa (n=1), Oceania (n=1) and transcontinental (n=1). SARS-CoV-2 infection of all enrolled participants was confirmed in all trials except the RECOVERY Trial that also included patients with probable infection. There were 3 trials (9%) with only ICU patients, and 19 trials (58%) where not all patients required intensive care, but all required oxygen. In 10 trials (30%), patients were recruited regardless of intensive care or oxygen requirement and one trial (3%) recruited only outpatients.

All participants received the usual local care. In 14 trials (42%), all patients received convalescent plasma within 14 days since symptom onset. The plasma was confirmed to have high antibody titers in 15 (45%) trials; and was obtained from donors with moderate or severe COVID-19 in 6 trials (18%). Twenty-three trials (70%) excluded women donors who were pregnant or had previously been pregnant (or who did not test negative for HLA antibodies). Patients randomized to the control group received in 24 (74%) trials no additional treatment than the usual local care and in 9 (26%) trials a placebo infusion.

The risk of bias was considered as low for 29 out of the 33 included trials. For 3 trials it was unclear due to inadequate description of the allocation concealment procedure or concerns about open label trials reported without patient flowcharts. Risk of bias was considered high for 1 trial due to missing information about potential protocol deviations (Additional file 5). Loss to follow-up was minimal (0% in 20 trials, ranging from 0.003 to 9% in 13 trials). Assessment of small study effects resulted in a statistically significant Egger’s test (p-value 0.046; Additional file 6).

Recruitment status of nonincluded trials
We surveyed 64 unpublished potentially eligible trials (i.e. eligibility based on the information provided in the registries) that were not included in this analysis for their current recruitment status. Out of the 64 trials, 14 were not yet recruiting (22%), 33 recruiting (52%), 2 terminated early (3%), 10 completed (16%), and 4 were withdrawn (6%) and one was not identifiable at the trial registry. However, the status of the 47 trials marked as recruiting or not yet recruiting remains unclear since their last registry update occurred at a median of August 2020 (IQR: May 2020 to December 2020). Investigators of 14 out of the 64 trials (22%) provided current accrual as of February/March, 2021, with a total of 3076 participants.
Fig. 1 (See legend on previous page.)
| Trial acronym and/or registration number | Location     | Status          | Blinding       | Control type       | N included (N planned) | Mortality % | Planned mortality time point<sup>a</sup> | Patient setting                        | Plasma titer, assay (timing of intervention) | Donor severity (HLA antibody status) |
|----------------------------------------|--------------|-----------------|----------------|--------------------|-----------------------|-------------|----------------------------------------|--------------------------------------------|------------------------------------------|-----------------------------------|
| Unpublished                            |              | Recruiting      | None           | Standard of care   | 12 (182)              | 16.67%      | 28 days                                | Inpatients with supplemental oxygen       | Low titer ≥ 1:200 S-RBD IgG, EUROMMUN (Maximum was < 14 days after symptom onset) | Mild to moderate (Excluding potentially HLA antibody positive persons) |
| LIFESAVER (NCT04374526)               | Italy        | Recruiting      | None           | Standard of care   | 90 (174)              | 13.33%      | 28, 56 and 84 days                     | Inpatients with supplemental oxygen       | Confirmed high-titer ≥ 180, neutralizing antibody assay (No exclusion based on timing of symptom onset) | Mild to severe (Excluding potentially HLA antibody positive persons) |
| RECOVER (EUCTR2020-001632-10-DE)      | Germany      | Recruiting      | None           | Standard of care   | 22 (100)              | 59.09%      | 3, 5, 7, 9, and 11 days                | Inpatients with supplemental oxygen       | No minimum cut-off (Maximum was < 14 days after symptom onset) | Mild to severe (Excluding potentially HLA antibody positive persons) |
| LACCPT (PACTR202006760881890)         | Nigeria      | Recruiting      | Participant, Care Provider | Placebo (normal saline) | 42 (80)              | 28.57%      | 15 days                                | Inpatients with supplemental oxygen       | Confirmed high-titer > 1000 S-RBD IgG, > 1:32 neutralizing, separate in-house assays (Maximum was > 14 days after symptom onset) | Mild to moderate (Excluding potentially HLA antibody positive persons) |
| CPC-SARS (NCT04405310)                | Mexico       | Recruiting      | Participant, Care Provider | Placebo (hartmann plus albumine) | 14 (50)              | 7.14%       | 28 days                                | Inpatients with supplemental oxygen       | Low-titer S-RBD IgG, Abbott Architect IgG (No exclusion based on timing of symptom onset) | NA (Not excluding potentially HLA antibody positive persons) |
| NCT04442191                           | United States| Recruiting      | Participant, Care Provider | Placebo (fresh frozen plasma) | 2 (10)               | 100%        | 28 days                                | Inpatients with supplemental oxygen       | NA                                      | NA (Not excluding potentially HLA antibody positive persons) |
| Trial acronym and/or registration number | Location | Status | Blinding | Control type | N included (N planned) | Mortality % | Planned mortality time point$^a$ | Patient setting | Plasma titer, assay (timing of intervention) | Donor severity (HLA antibody status) |
|----------------------------------------|----------|--------|----------|--------------|------------------------|-------------|---------------------------------|----------------|--------------------------------------------|----------------------------------|
| NCT04385199                            | United States | Recruiting | None | Standard of care | 30 (30) | 16.67% | NR | Inpatients with supplemental oxygen | No minimum cut-off | NA (NA) |
| NCT04403477 (NCT04403477)$^b$        | Bangladesh | Recruiting | None | Standard of care | 30 (60) | 18.33% | 28 days | Inpatients with supplemental oxygen | Low titer: $\geq$ 1:160 S-RBD IgG, EUROIMMUN (Maximum was $< 14$ days after symptom onset) | Moderate to severe (Excluding potentially HLA antibody positive persons) |
| PLACO-COVID (NCT04428021)             | Italy | Active, not recruiting | Participant, Care Providers, Outcomes Assessor | Standard of care | 120 (180)$^c$ | 15.83% | 30 days | Inpatients with supplemental oxygen | No minimum cut-off | Mild to severe (Excluding potentially HLA antibody positive persons) |
| REMAP-CAP (NCT02735707)               | International | Terminated | None | Standard of care | 2014 (N/A) | 34.26% | 90 days | ICU | Confirmed high-titer: $\geq$ 1:100 neutralizing or equivalent. In the UK: EUROIMMUN S/C $\geq$ 6 (No exclusion based on timing of symptom onset) | NA (Excluding potentially HLA antibody positive persons) |
| ASCOT (NCT04483960)                   | Australia and New Zealand | Terminated | None | Standard of care | 33 (N/A) | 9.09% | 28 days | Inpatients with or without supplemental oxygen | Confirmed high-titer: $\geq$ 180, neutralizing assay by Walker et al. (2021) (Maximum was $< 14$ days after symptom onset) | NA (Excluding potentially HLA antibody positive persons) |
| Trial acronym and/or registration number | Location       | Status   | Blinding    | Control type        | N included (N planned) | Mortality % | Planned mortality time point | Patient setting                                                                 | Plasma titer, assay (timing of intervention)                                                                 | Donor severity (HLA antibody status)                                                                 |
|------------------------------------------|----------------|----------|-------------|---------------------|------------------------|-------------|------------------------------|--------------------------------------------------------------------------------|---------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Co-CLARITY (NCT04567173)                | Philippines    | Recruiting | None        | Standard of care    | 25 (136)               | 0.00%       | 28 days                      | Inpatients with or without supplemental oxygen                                 | Low titer: Ortho VITROS S/C ≥ 5 (Maximum was ≤ 14 days after symptom onset)    | Moderate to severe (Excluding potentially HLA antibody positive persons)        |
| NCT04528368                             | Brazil         | Recruiting | None        | Standard of care    | 16 (60)                | 0.00%       | 7, 10, 14, 21 and 28 days   | Inpatients with or without supplemental oxygen                                 | Low titer: ≥ 1320 S-RBD IgG, in-house assay (Maximum was ≤ 14 days after symptom onset) | NA (Excluding potentially HLA antibody positive persons)                        |
| CAPSID (NCT04433910)                    | Germany        | Recruiting | None        | Standard of care    | 5 (106)                | 0.00%       | 21, 35 and 60 days          | ICU                                                                             | No minimum cut-off (No exclusion based on timing of symptom onset)            | NA (Not excluding potentially HLA antibody positive persons)                   |
| PERUCONPLASMA (NCT04497324)             | Peru           | Recruiting | None        | Standard of care    | 25 (100)               | 16.00%      | 30 days                      | Inpatients with supplemental oxygen                                             | Confirmed high-titer: EUROMUN S/C > 5.0 (No exclusion based on timing of symptom onset) | Moderate to severe (Excluding potentially HLA antibody positive persons)        |
| NCT04332835                             | Colombia       | Completed | Outcome Assessor | Standard of care | 100 (92)              | 8.00%       | 7, 14 and 28 days           | Inpatients with supplemental oxygen                                             | Confirmed high-titer: IgG ≥ 1/3200 and IgA ≥ 1/800 by EUROMUN All transfused plasma presented neutralizing antibodies ≥ 1/256 (No exclusion based on timing of symptom onset) | Moderate to severe (Excluding potentially HLA antibody positive persons)        |
Table 1 (continued)

| Trial acronym and/or registration number | Location | Status       | Blinding     | Control type | N included (N planned) | Mortality % | Planned mortality time point | Patient setting | Plasma titer, assay (timing of intervention) | Donor severity (HLA antibody status) |
|-----------------------------------------|----------|--------------|--------------|--------------|------------------------|-------------|-----------------------------|-----------------|--------------------------------------------|-----------------------------------|
| CONFIDENT (NCT04558476)                | Belgium  | Recruiting   | None         | Standard of care | 301 (500)              | 31.89%      | 28 and 90 days ICU          | NA (Excluding potentially HLA antibody positive persons) |
| PC/COVID-19 (NCT04366245)              | Spain    | Completed    | None         | Standard of care | 41 (72)                | 2.44%       | 14 and 28 days              | NA (Excluding potentially HLA antibody positive persons) |
| COP-COVID-19 (NCT04358783)             | Mexico   | Recruiting   | Participant, Care Provider | Standard of care | 31 (30)                | 35.48%      | 14 days                     | NA (Excluding potentially HLA antibody positive persons) |
| NCT04600440                            | Sweden   | Terminated   | None         | Standard of care | 31 (100)               | 16.13%      | 90 days                     | NA (Excluding potentially HLA antibody positive persons) |

Mild to moderate (Excluding potentially HLA antibody positive persons)

**Note:** Planned mortality time point is the planned period for assessing mortality post-intervention.
### Table 1 (continued)

| Trial acronym and/or registration number | Location          | Status     | Blinding                        | Control type                        | N included (N planned) | Mortality % | Planned mortality time point\(^a\) | Patient setting                        | Plasma titer, assay (timing of intervention) | Donor severity (HLA antibody status) |
|------------------------------------------|-------------------|------------|---------------------------------|-------------------------------------|------------------------|-------------|-------------------------------------|------------------------------------------|------------------------------------------|----------------------------------|
| CCAP-2 (NCT04345289)                    | Denmark           | Terminated | Participant, Care Providers, Outcome Assessor | Placebo (normal saline)             | 144 (1,100)            | 11.11%      | 7, 14, 21, 28 and 90 days           | Inpatients with or without supplemental oxygen | Other titer level\(^b\) (No exclusion based on timing of symptom onset) | NA (Excluding potentially HLA antibody positive persons) |
| Published                                |                   |            |                                 |                                     |                        |             |                                     |                                          |                                          |                                  |
| ChiCTR2000029757                         | China             | Terminated | None                            | Standard of care                    | 103 (200)              | 19.42%      | 28 days                            | Inpatients with supplemental oxygen         | Confirmed high-titer: ≥ 1640 S-RBD IgG, in-house assay (NA) | NA (NA)                                  |
| NCT04342182                              | Netherlands       | Terminated | None                            | Standard of care                    | 86 (426)               | 19.77%      | 60 days                            | Inpatients with or without supplemental oxygen | Low titer: ≥ 1400 S-RBD IgG, assay missing (No exclusion based on timing of symptom onset) | NA (Excluding potentially HLA antibody positive persons) |
| NCT04392414                              | Russia            | Completed  | None                            | Placebo (fresh frozen plasma)       | 66 (60)                | 6.06%       | 30 days                            | Inpatients with or without supplemental oxygen | Confirmed high-titer: ≥ 1:1000 S-RBD IgG, in-house assay (Maximum was = < 14 days after symptom onset) | Moderate to severe (Not excluding potentially HLA antibody positive persons) |
| ConPlas-19 (NCT04345523)                 | Spain             | Terminated | None                            | Standard of care                    | 81 (278)               | 4.94%       | 29 days                            | Inpatients with or without supplemental oxygen | Confirmed high-titer: > 1:80, neutralizing assay (Maximum was = < 14 days after symptom onset) | NA (NA)                                  |
| PLACID (CTRI/2020/04/024775)             | India             | Completed  | None                            | Standard of care                    | 464 (452)              | 14.01%      | 28 days                            | Inpatients with supplemental oxygen         | No minimum cut-off (No exclusion based on timing of symptom onset) | Mild to moderate (Excluding potentially HLA antibody positive persons) |
| Trial acronym and/or registration number | Location | Status | Blinding | Control type | N included (N planned) | Mortality % | Planned mortality time point | Patient setting | Plasma titer, assay (timing of intervention) | Donor severity (HLA antibody status) |
|----------------------------------------|----------|--------|----------|--------------|-----------------------|-------------|-----------------------------|----------------|---------------------------------------------|----------------------------------|
| ILBS-COVID-02 (NCT04346446)           | India    | Completed | None     | Placebo (fresh frozen plasma) | 31 (40) | 3.23% | 28 days | Inpatients with supplemental oxygen | No minimum cut-off (No exclusion based on timing of symptom onset) | NA (Excluding potentially HLA antibody positive persons) |
| NCT04356534                           | Bahrain  | Completed | None     | Standard of care | 40 (40) | 7.50% | 28 days | Inpatients with supplemental oxygen | No minimum cut-off (Maximum was <= < 14 days after symptom onset) | Moderate to severe (Excluding potentially HLA antibody positive persons) |
| PLASM-AR (NCT04383535)                | Argentina| Completed | Participant, Care Provider | Placebo (normal saline) | 333 (333) | 11.11% | 30 days | Inpatients with or without supplemental oxygen | Confirmed high-titer: ≥ 1800 S-RBD IgG, COVIDAR IgG test (No exclusion based on timing of symptom onset) | Mild to moderate (Excluding potentially HLA antibody positive persons) |
| PICP19 (CTRI/2020/05/025209)          | India    | Completed | None     | Standard of care | 80 (80) | 30.00% | 30 days | Inpatients with supplemental oxygen | No minimum cut-off (Maximum was <= < 14 days after symptom onset) | NA (Excluding potentially HLA antibody positive persons) |
| NCT04479163                           | Argentina| Terminated | Participant, Care Provider | Placebo (normal saline) | 160 (210) | 3.75% | 25 days | Outpatients | Confirmed high-titer: > 1.1000 COVIDAR IgG (Instituto Leloir, Argentina) (Maximum was <= < 14 days after symptom onset) | NA (NA) |
Table 1 (continued)

| Trial acronym and/or registration number | Location   | Status       | Blinding | Control type | N included (N planned) | Mortality % | Planned mortality time point\(^a\) | Patient setting | Plasma titer, assay (timing of intervention) | Donor severity (HLA antibody status) |
|----------------------------------------|------------|--------------|----------|--------------|-----------------------|-------------|------------------------------------|-----------------|---------------------------------------------|--------------------------------------|
| RECOVERY Trial (NCT04381936)           | United Kingdom | Terminated   | None     | Standard of care | 11.558 (N/A)          | 24.28%      | 28 days                            | Inpatients with or without supplemental oxygen | Confirmed high-titer ≥ 1:100 neutralizing (EUROIMMUN IgG, ELISA S/C ≥ 6.0) (No exclusion based on timing of symptom onset) | NA (Excluding potentially HLA antibody positive persons) |
| NCT04359810                            | United States | Completed    | Participant, Outcomes Assessor | Placebo (fresh frozen plasma) | 223 (219)           | 16.59%      | 28 days                            | Inpatients with or without supplemental oxygen | Low titer ≥ 1:400 S-RBD IgG, in-house assay (No exclusion based on timing of symptom onset) | NA (NA) |
| IRCT20200310046736NI\(^b\)             | Iran       | Completed    | Participant, Outcome Assessor | Standard of care | 62 (62)             | 12.90%      | 60 days                            | Inpatients with supplemental oxygen | No minimum cut-off (Maximum was ≤ 14 days after symptom onset) | NA (Excluding potentially HLA antibody positive persons) |

\(^a\) For published trials, we report the planned time point (after randomization) stated in the publications and used for our meta-analysis. For unpublished trials, we report the planned time points as reported in the registries and for the meta-analysis, we used the mortality data available at the time-point of the request, which may not reflect the planned time points (or future publications reporting on it).

\(^b\) NCT04403477 compares two different volumes of plasma (a) 400 mL and (b) 200 mL versus standard of care.

\(^c\) The multi-arm PLACO-COVID trial includes another experimental arm (N = 60) treated with standard therapy + standard plasma, a treatment not considered in this review.

\(^d\) CCAP-2 initially used a EUROIMMUN cutoff of > 3.0, which was changed to > 3.5 after the March 2021 update of the US FDA emergency use authorization with its new guidance. For this meta-analysis, it is categorized as non-high titer.

\(^e\) IRCT20200310046736NI was published after the last literature search on April 8th, 2021. The trial team made us aware of their publication.
recruited out of a total target sample size of 3989 participants (median recruitment 80 participants, IQR 0 to 483; median proportion of target sample 55%, IQR 6 to 100%). The total target sample size of all unavailable completed or terminated trials was 1457 participants (median 88 participants, IQR 55 to 142). Of the 97 eligible trials (33 included and 64 not included), there is evidence available from at least 20,499 participants, of which at least 4022 participants (20%) are enrolled in unpublished trials that we have not included in this analysis.

All-cause mortality
Overall, 3949 of 16,477 patients died (24%). The mortality in patients treated with plasma was 23% (1997/8495) versus 24% (1952/7982) in patients in the various control groups. The mortality rates in the control groups varied considerably ranging from 0 to 54% (median 15% IQR 10 to 25%), with nine trials with a mortality rate of 25% and above in their control groups. The combined RR for all-cause mortality was 0.97 (95% CI [0.92; 1.02]; p-value=0.25) (Fig. 2). There was no between-study heterogeneity beyond that expected by chance ($I^2=0$; $tau^2=0$, 95% CI [0; 0.12]). In 3 trials including 47 patients, there were zero deaths in both arms. The RECOVERY Trial and the unpublished REMAP-CAP trial accounted for 69.8% and 19.7% of the weight in the meta-analysis, and 70% (11,558/16,477) and 12% (2014/16,477) of the patients included, respectively. The unpublished evidence overall accounted for 25.3% of the weight in the meta-analyses and 3190 of the 16,477 patients included (19%).

The sensitivity analyses employing different meta-analytical methods results were compatible with the main analysis (Additional file 7). No potential effect modifiers were detected (Fig. 3).

Accumulation of evidence in published and unpublished trials
The accumulation of evidence generated through publications and the addition of unpublished data through the collaborative effort was characterized by two major shifts in the treatment effect estimates over time (Fig. 4). For a short period of time, when 4 trials were available, the cumulative meta-analysis suggested a nominally significant benefit ($p=0.03$; with limited evidence, however, as transient nominally significant results upon sequential addition of trials can be misleading) [43]. The first shift occurred with the publication of the PLACID trial (before September 10th, 2020 RR 0.58, 95% CI [0.38; 0.90]; with the PLACID trial RR 0.84 95% CI [0.53; 1.34]), and the second shift occurred when the RECOVERY Trial was posted as a preprint (before March 10th, 2021 RR 0.84, 95% CI [0.65; 1.09]; with the RECOVERY trial RR 0.98, 95% CI [0.92; 1.04]). The addition of the unpublished trial evidence greatly increased the precision of the effect estimate (before unpublished trials RR 0.96, 95% CI [0.88; 1.05]; with the unpublished trials RR 0.97, 95% CI [0.92; 1.03]) and also corroborates the findings of the RECOVERY Trial, showing highly similar effects (RECOVERY RR 0.99, 95% CI [0.93; 1.05] versus unpublished combined RR 0.97, 95% CI [0.87; 1.07]).

Discussion
This meta-analysis of 33 clinical trials, including 16,477 patients with COVID-19, showed that treatment with convalescent plasma did not decrease all-cause mortality and confidence intervals excluded a meaningful clinical effect. This analysis is the largest available body of randomized clinical trial evidence on treatment benefits of convalescent plasma in COVID-19 to-date. There was no indication that the treatment was associated with more or less benefit in patients with different disease severity or with the type of plasma, but data for subgroup analyses were sparse. Only few trials assessed early administration of plasma and further analyses are required to investigate a potential effect modification of the timing of the intervention, and whether patients have already developed their own antibodies by the time of the treatment. The vast majority of trials included patients with moderate or severe COVID-19 who needed hospitalization and it is unclear if the results are applicable to outpatients.

In addition to providing the most complete body of evidence including all available mortality data, our collaborative approach was also driven by the opportunity to allow all trials to publicly share their data regardless of their planned sample size or final results. Beyond reducing research waste, such collaboration of trial investigators and evidence synthesis aims to inform the generation of clinical trial evidence and the application of evidence for clinical care in a timely fashion [44].

The evidence base was dominated by the RECOVERY Trial and REMAP-CAP, which accounted for 89.5% of the weight in the meta-analysis and 82% of the patients included. For both trials, the lack of benefit on mortality outcomes were initially communicated through press releases. Those highly anticipated announcements might have had an impact on the future of clinical trials assessing convalescent plasma. Since February 4, 2021, the emergency use authorization in the US no longer authorizes use in outpatients, patients beyond an early disease stage or of low-titer plasma [34] followed by similar changes in the European Commission’s guidance for monitored use [10]. Although this authorization does not apply to trials, recruitment for trials including such patients or low-titer treatments could become more difficult. Out of the 33 included RCTs, 9 have been
terminated early; moreover, out of 64 eligible trials not included, at least four were withdrawn, two terminated early, and more might follow. However, the remaining amount of evidence that is not covered by this analysis is small.

Traditional systematic reviews have many strengths, but they take time and may struggle to capture unpublished data. Others have highlighted the need for an accelerated evidence synthesis regarding the benefits and harms of COVID-19 interventions such as convalescent plasma [45], suggesting a rapid review approach or continuously updated (living) systematic reviews (LSR), particularly ones that incorporate emerging technologies to automate certain aspects of the review process. LSRs are valuable [46, 47], but are dependent on traditional availability of data, which can be slower than needed in urgent contexts. Our approach, built on a similar strategy used to investigate hydroxychloroquine/chloroquine [48] was designed to accelerate the evidence synthesis for rapid provision of urgently needed information to guide clinical decision making. We offered investigators the opportunity to share trial results regardless of trial or publication status, which was done only after careful

| Trial               | Published | Country               | Events, Plasma (n/N) | Events, Control (n/N) | Favours Plasma | Favours Control | RR (95% CI) % weight (random) |
|---------------------|-----------|-----------------------|----------------------|-----------------------|----------------|----------------|--------------------------------|
| ILBS–COVID–02       | India     | 3/15                  | 1/16                 |                       | 3.20 [0.37; 27.49] | 0.4            |                                |
| PLACID              | India     | 34/235                | 31/229               |                       | 1.07 [0.68; 1.68]  | 1.4            |                                |
| RECOVERY            | United Kingdom | 1399/5796 | 1408/5763            |                       | 0.99 [0.93; 1.05]  | 69.8           |                                |
| PLASM–AR            | Argentina | 25/228                | 12/105               |                       | 0.96 [0.50; 1.63]  | 0.7            |                                |
| PICP19              | India     | 10/40                 | 14/40                |                       | 0.71 [0.36; 1.41]  | 0.6            |                                |
| ChiCTR2000029757    | China     | 8/52                  | 12/51                |                       | 0.65 [0.29; 1.47]  | 0.4            |                                |
| RECOVERY            | Iran      | 3/31                  | 5/31                 |                       | 0.60 [0.16; 2.30]  | 0.2            |                                |
| NCT03432182         | Netherlands | 6/43                 | 11/43                |                       | 0.55 [0.22; 1.34]  | 0.4            |                                |
| NCT034359810        | United States | 19/150               | 18/73                |                       | 0.51 [0.29; 0.92]  | 0.9            |                                |
| NCT04479163         | Argentina | 1/20                  | 2/20                 |                       | 0.50 [0.05; 5.08]  | 0.1            |                                |
| NCT04392414         | Russia    | 2/46                  | 2/20                 |                       | 0.43 [0.07; 2.87]  | 0.1            |                                |
| ConPlas–19          | Spain     | 0/38                  | 4/43                 |                       | 0.01 [0.00; 2569.79] | 0.0           |                                |

**Random effects model**

Heterogeneity: $\tau^2 = 2\%$, $\chi^2 = 0.0007, p = 0.43$

**Unpublished**

- NCT04332835: Colombia
  - 6/49: 2/51
  - Risk Ratio (95% CI): 3.12 [0.66; 14.73] $p = 0.1$

- CCAP–2: Denmark
  - 13/98: 3/46
  - Risk Ratio (95% CI): 2.03 [0.61; 6.79] $p = 0.2$

- LIFESAVER: Italy
  - 1/4: 1/8
  - Risk Ratio (95% CI): 2.00 [0.16; 24.33] $p = 0.0$

- PLACO–COVID: Italy
  - 12/60: 7/60
  - Risk Ratio (95% CI): 1.71 [0.72; 4.05] $p = 0.4$

- LACPT: Nigeria
  - 7/11: 6/11
  - Risk Ratio (95% CI): 1.17 [0.58; 2.35] $p = 0.6$

- RECOVER: Germany
  - 6/43: 6/47
  - Risk Ratio (95% CI): 1.09 [0.38; 3.13] $p = 0.3$

- REMAP–CAP: International
  - 367/312: 323/332
  - Risk Ratio (95% CI): 0.98 [0.87; 1.10] $p = 19.7$

- COP–COVID: Mexico
  - 7/20: 4/11
  - Risk Ratio (95% CI): 0.98 [0.36; 2.57] $p = 0.3$

- CONFIDENT: Belgium
  - 45/150: 51/151
  - Risk Ratio (95% CI): 0.89 [0.64; 1.24] $p = 2.6$

- NCT034385199: United States
  - 3/20: 2/10
  - Risk Ratio (95% CI): 0.75 [0.15; 3.79] $p = 0.1$

- PC/C0VID–19: Spain
  - 2/38: 3/36
  - Risk Ratio (95% CI): 0.63 [0.11; 3.56] $p = 0.1$

- NCT04403747: Bangladesh
  - 3/20: 2.5/10
  - Risk Ratio (95% CI): 0.60 [0.13; 2.68] $p = 0.1$

- NCT04403747: Bangladesh
  - 3/20: 2.5/10
  - Risk Ratio (95% CI): 0.60 [0.13; 2.68] $p = 0.1$

- ASCOT: Australia and New Zealand
  - 1/15: 2/18
  - Risk Ratio (95% CI): 0.60 [0.06; 5.99] $p = 0.1$

- NCT04600440: Sweden
  - 2/17: 3/14
  - Risk Ratio (95% CI): 0.55 [0.11; 2.84] $p = 0.1$

- PERUCO.PlASMA: Peru
  - 1/12: 3/13
  - Risk Ratio (95% CI): 0.36 [0.04; 3.02] $p = 0.1$

- CPC–SARS: Mexico
  - 6/31: 6/11
  - Risk Ratio (95% CI): 0.35 [0.14; 0.87] $p = 0.4$

- NCT04424191: United States
  - 0/8: 1/6
  - Risk Ratio (95% CI): 0.11 [0.00; 17.06] $p = 0.0$

- Co-CLARITY: Philippines
  - 0/3: 0/12
  - Risk Ratio (95% CI): 0.00 [0.00; 0.00] $p = 0.0$

- NCT04528368: Brazil
  - 0/9: 0/8
  - Risk Ratio (95% CI): 0.00 [0.00; 0.00] $p = 0.0$

**Random effects model**

Heterogeneity: $\tau^2 = 0\%$, $\chi^2 = 0, p = 0.64$

**Random effects model**

Heterogeneity: $\tau^2 = 0\%$, $\chi^2 = 0, p = 0.65$

Test for overall effect: $p = 0.25$

![Fig. 2](image-url) Random effects meta-analysis on the association between convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, stratified by publication status. CI confidence interval, RR risk ratio. NCT04403477 compares two different volumes of plasma a 400 mL and b 200 mL versus standard of care. To avoid double counting the control arm, the number of patients and number of events were split equally between the two comparisons.
consideration and approval of principal investigators and data steering committees.

Our collaboration focused on aggregated data of one critical outcome, robust to various types of bias: all-cause mortality. We encouraged teams to continue their plans for individual publications, which will display the granularity not captured by our rapid approach, as well as to participate in other collaborations. We are aware of one other international real-time collaboration, the Continuous Monitoring of Pooled International Trials of Convalescent Plasma for COVID-19 Hospitalized Patients (COMPILE) project [49], a highly granular, individual patient data meta-analysis including eight trials [50].

We identified almost a hundred eligible trials that evaluate evidence on convalescent plasma treatment in patients with COVID-19. Among 21 other systematic reviews and meta-analyses on this topic that were available on PubMed as of mid-April, 2021 [5, 46, 47, 51–68], 15 include only 0 to 2 randomized trials alongside observational studies (e.g., two LSR) [46, 47, 51–63] and the two most comprehensive reviews included 10 RCTs [5, 64]. One of the latter meta-analyses [5] does not include the RECOVERY Trial and includes one trial that we categorized as non-randomized [69]. The other meta-analysis, authored by some members of our team [64] included four peer-reviewed articles, five preprints

| Subgroups                                      | N Comparisons | N patients Plasma | N patients Control | Favours Plasma | Favours Control | RR (CI 95%) | P-value |
|-----------------------------------------------|---------------|-------------------|--------------------|----------------|----------------|------------|---------|
| **Publication status**                        |               |                   |                    |                |                |            |         |
| Published                                     | 13            | 6773              | 6514               |                |                | 0.96 [0.88; 1.05] | 0.95    |
| Unpublished                                   | 18            | 1698              | 1445               |                |                | 0.97 [0.87; 1.07] |         |
| **Control type**                              |               |                   |                    |                |                |            |         |
| Placebo                                       | 9             | 667               | 368                |                |                | 0.77 [0.47; 1.27] | 0.28    |
| Standard of care                              | 22            | 7804              | 7591               |                |                | 0.98 [0.94; 1.02] |         |
| **Confirmed high-titer**                      |               |                   |                    |                |                |            |         |
| Yes                                           | 15            | 7681              | 7342               |                |                | 0.97 [0.92; 1.03] | 0.54    |
| No                                            | 16            | 790               | 617                |                |                | 0.91 [0.72; 1.16] |         |
| **High titer given within 14 days of symptoms onset in hospitalized patients** | | | | | | | |
| No                                            | 27            | 8344              | 7850               |                |                | 0.97 [0.92; 1.03] | 0.04    |
| Yes                                           | 3             | 99                | 81                 |                |                | 0.47 [0.10; 2.20] |         |
| **Patient Setting**                           |               |                   |                    |                |                |            |         |
| Inpatients with or without supplemental oxygen | 8             | 4143              | 6111               |                |                | 0.87 [0.64; 1.17] | 0.64    |
| Inpatients with supplemental oxygen            | 20            | 746               | 685                |                |                | 0.90 [0.72; 1.12] |         |
| ICU                                           | 2             | 1232              | 1083               |                |                | 0.97 [0.65; 1.44] |         |
| Outpatients                                   | 1             | 80                | 80                 |                |                | 0.50 [0.09; 2.65] |         |
| **Treatment started within 14 days of symptoms onset** | | | | | | | |
| No                                            | 17            | 8036              | 7570               |                |                | 0.92 [0.74; 1.13] | 0.28    |
| Yes                                           | 13            | 383               | 338                |                |                | 0.79 [0.63; 0.98] |         |
| **Donor COVID-19 severity**                   |               |                   |                    |                |                |            |         |
| Mild to moderate                              | 6             | 553               | 403                |                |                | 0.85 [0.53; 1.36] | 0.09    |
| Mild to severe                                | 3             | 114               | 118                |                |                | 1.30 [0.73; 2.31] |         |
| Moderate to severe                            | 6             | 167               | 124                |                |                | 0.75 [0.32; 1.78] |         |
| **Excluding potentially HLA antibody positive persons** | | | | | | | |
| Yes                                           | 24            | 8077              | 7676               |                |                | 0.98 [0.92; 1.04] | 0.28    |
| No                                            | 2             | 54                | 26                 |                |                | 0.37 [0.00; 34923.14] |         |
| **Countries**                                 |               |                   |                    |                |                |            |         |
| Middle-income                                 | 15            | 912               | 709                |                |                | 0.85 [0.67; 1.09] | 0.51    |
| High-income                                   | 15            | 6501              | 6341               |                |                | 0.98 [0.92; 1.04] |         |
| Middle- and high-income                       | 1             | 1082              | 932                |                |                | 0.98 [0.87; 1.10] |         |

Fig. 3 Subgroup analyses. CI confidence interval, ICU intensive care unit, RR risk ratio. Subgroup analyses include only trials with at least one event in one arm (i.e. trials with zero events in both arms were excluded). Number of comparisons differ from number of trials as two trials had more than one comparison. We defined high-titer as S-protein receptor binding domain (RBD)-specific IgG antibody titer of 1:640 or higher, or serum neutralization titer of 1:40 or higher. For studies using the Ortho VITROS SARS-CoV-2 IgG test, which reports a signal-to-cutoff (S/C) value, we defined high titer as S/C > 12 (corresponding to the initial United States Food and Drug Administration emergency use authorization) as prespecified. We complemented the high-titer definition with additional information made available in the March 2021 version emergency use authorization, e.g., EUROMMUN (ratio ≥ 3.5) and Abbott ARCHITECT (S/C ≥ 4.5)
and the RECOVERY Trial press release and showed no statistically significant benefits for mortality or other clinical outcomes. The project described here is the only meta-analysis with a collaborative approach that captures ongoing randomized trial evidence regardless of status. We regard our design as complementary to traditional systematic reviews. Whereas comprehensive inclusion of results unavailable through traditional venues may be helpful in evidence synthesis [70, 71], non-peer-reviewed results should be viewed with more caution. This trade-off between quality control and results availability may become a more pressing issue as preprints are becoming more popular means of disseminating clinical trial evidence [70, 71].

We encourage trial investigators to coordinate early on in the design and conduct of their RCTs. Beyond providing evidence for clinical decision making, such an approach can foster evidence-based research and strategic evidence generation in situations where several trial teams address the same urgent research questions. Collaborative meta-analyses of ongoing trials do not provide final evidence but could be crucial to guide clinical decisions as well as data steering committee decisions.

Several limitations with our review should be considered. First, we only examined mortality. However, all-cause mortality in hospitalized COVID-19 patients is arguably the most important patient-relevant outcome in this setting; can be reliably measured; is most robust against sources of bias; and can be rapidly collected from diverse trials without complex data harmonization. Consistent results in the subset of placebo-controlled trials, the fact that attrition was overall negligible, and that all trials were randomized (as confirmed for all unpublished trials by investigators) further corroborated that the overall risk of bias within the trials is probably not high. However, it cannot be ruled out that the self-selected response from unpublished trial teams may introduce a reporting bias, e.g. if willingness to contribute data to the collaborative analysis depended on the results of interim trial analyses, as suggested by the Egger’s test. Nevertheless, the potential reporting bias is unlikely to change our interpretation of the results as we believe that small studies with null results were less likely to be shared with us and would contribute little to the overall evidence.

Second, we had limited ability to address potential effect modification by the timing, dose, or titer for plasma treatment. We also did not collect detailed information on various patient characteristics, including age, sex, comorbidities, and concomitant treatment (including dexamethasone) disclosed in individual trial publications which would allow further insights on potentially smaller or greater benefits in certain subgroups. For example, the trials in this meta-analysis did not specifically study patients with B-cell depletion or other immunodeficiences. Moreover, as the participants in all included trials except one were hospitalized at enrollment, representing a group with moderate to critical COVID-19, results have unclear applicability to outpatients.

According to our search, nine outpatient trials (one terminated, seven with ongoing recruitment and one not yet started) are in the pipeline. In their updated emergency use authorization,
the US FDA restricted the authorization to the use of high-titer plasma in hospitalized patients early in the course of the disease [34]. While early administration of high-titer plasma has been advocated also elsewhere [1], only a small minority of RCTs have applied this regimen. Four of 32 RCTs here included used early administration of high-titer plasma in hospitalized patients (ASCOT, ConPlas-19, REMAP-CAP, and NCT04392414), and one in outpatients (NCT04479163), and our study-level analysis did not find subgroup effects regarding titer or timing. Although our definition of high-titer was chosen to conform with US FDA guidance, there is still a limited amount of comparative data between assays used in different countries (and in some cases, individual working groups) to translate titer levels. It cannot be excluded that patients treated earlier within the onset of symptoms, or with milder COVID-19, may benefit from treatment with convalescent plasma. As the majority of included RCTs are ongoing, they are expected to contribute more evidence in the coming months, together with additional evidence from individual patient data meta-analyses, e.g., the COMPile project [49]. This may shed light on important outcomes other than all-cause mortality (e.g., severe respiratory disease or hospitalization rate), as well as possible subgroup effects such as early administration of high-titer plasma.

Third, our subgroup analyses in some cases made use of arbitrary categorizations, albeit chosen to be consistent with clinical practice, such as for plasma antibody titers and the timing of treatment initiation. The specification of subgroups was published in the protocol before data were obtained and analyzed. We consider all subgroup analyses exploratory and caution is warranted in interpreting such results.

Fourth, although representing a collaboration across many different countries, no data from any low-income countries were available, potentially limiting the applicability of our findings to these specific settings. Among all identified potentially eligible trials, one was situated in a low-income country (COVIDIT, Uganda; registered as NCT04542941).

Finally, even though this kind of collaborative meta-analysis relies on a detailed protocol with prespecified analyses aiming to ensure its integrity and validity, a few amendments were necessary. First, we realized the risk of bias assessment was readily feasible and added it post-hoc. Second, we did not specify a follow-up time point for the outcome assessment. We retained the latest one communicated to us; all updates requests were made systematically to all teams. Finally, we added some non-pre-specified analyses and these are stated as such.

**Conclusions**

Treatment with convalescent plasma for COVID-19 was not shown to reduce mortality and confidence intervals excluded a meaningful clinical effect. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care.

**Abbreviations**

COVID-19: Coronavirus 19; ELIA: Emergency use authorization; FDA: US Food and Drug Administration; HRQoL: Health-related quality of life; IQR: Interquartile range; ICU: Intensive care unit; IgG: Immunoglobulin G; LSR: Living systematic review; PM: Paule and Mandel; RBD: Receptor binding domain; RCT: Randomized clinical trial; SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus; S/C value: Signal-to-cutoff value.

**Supplementary Information**

The online version contains supplementary material available at [https://doi.org/10.1186/s12879-021-06829-7](https://doi.org/10.1186/s12879-021-06829-7).

---

**Acknowledgements**

We would like to express our warm gratitude to all participating patients and convalescent plasma donors. We thank Katja Suter and Sina Ullrich, University of Basel, for their administrative assistance. For their helpful contribution to individual trials, we thank Erica Wood, Iain Gossell, Richard Charlewood, Thomas Hills, Veronica Hoad, Kristina Kairaaitis, Akaj, Jindal, John Gerrard, Hong Foo, Adam Stwart, and Nanette Trask (ASCOT trial); Amalia Bravo-Lindoro, Raúl Carrillo-Espier, Karla Maldonado-Silva, Catalina Casillas-Suárez, Orlando Carrillo-Torres, Sandra Murrieta, Elizabeth Díaz-Padilla, Eli Omar Zavaleta, Yadira Bejar-Ramírez, and Evelyn Cortina-de la Rosa (CPC-SARS trial); Sheri Renaud, Roel Rolandio-Almarío, and Jacqueline Day (NCT04385199 trial); Sandra Tingqgård, MD, Karen Borup Heje Pedersen, MD, Michaela Tinggaard, MD, Louise Thorlacius-Ussing, MD, Clara Lundtoftt Claussen, MD, Nicholas Hovmand, MD, Simone Bastrup Iversen, MD, Caecile Leding, MD, Katrine Iversen, MD, Maria Engel Møller, MD, Håkon Sandholdt, MSc biostatistician (CCAP-2 trial).

For helpfully communicating details of their trial, we thank members of the PlasmAr trial, NCT04359810 trial (Max O’Donnell), and Technology—Philippine Council for Health Research and Development team would like to extend their gratitude to the Department of Science and Technology—Philippine Council for Health Research and Development and the UP-Philippine General Hospital for all their support in the setting up and conduct of the trial. For helpfully communicating details of their trial, we thank members of the PlasmAr trial, NCT0439810 trial (Max O’Donnell),
Authors' contributions
C.A. and P.J. contributed equally to this work. L.G.H., C.A., and P.J. have had full access to all data in this study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: C.A., P.J., A.M.S., E.R.S., D.M., S.N.G., J.P.A.I., L.G.H. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: C.A., P.J., L.G.H. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: P.J., C.A., A.M.S., S.N.G., J.P.A.I., L.G.H. Obtained funding: J.P.A.I., L.G.H. Administrative, technical, or material support: C.A., P.J., A.M.S., E.R.S., L.G.H. Supervision: L.G.H. Administrative, technical, or material support (through substantial contribution to individual trials): A.C.B., J.D., J.S.D., J.T.D., NEH, V.J., L.E.L., Z.K.M., J.S.M., S.C.M., M.V., N.O.S., D.L.P., N.P., D.M.A.R., J.A.R., B.A.R., J.S., T.S., S.Y.C.T., B.V. (ASCOT); A.C. (CAPSID); T.E., H.N., L.W. (CCAP-2); M.A.A., R.N.A., M.A.C.A., L.B.B., J.M.C., J.G.R.C., F.M.M.C., C.F.N.C., T.E.D., C.C.D., I.M.S.E., A.L.M.E., D.T.V.G., F.M.H., I.L., J.A.C., L.C.L., S.C.M., F.A.G.M., A.L.M., J.A.V.M., A.K.H.Q., M.C.M.S., P.Y.T., J.D.V. (Co-CLARITY); V.A., D.D., A.M.H., D.G., E.H., P.F.L., G.M., B.M., M.M.2, T.N. (CONFIDENT); A.C.O., E.G.G., D.G.A., J.M.L.D., E.P.A. (COP-A.C.2, L.T. (LIFESAVER); Y.A.A., J.M.A., B.C., J.C.D.C., J.E.G., P.A.G.G., J.S.G.G., R.D.M., M.C.M.S., P.Y.T., J.D.V.

NCT04668009 trial, and CTRI/2020/05/025299 trial. Support for title page creation and format was provided by AuthorArranger, a tool developed at the National Cancer Institute (https://www.cancer.gov/).

For statistical modeling and design of REMAP-CAP). Dr. Castillo reports grants from National Cancer Institute (https://www.cancer.gov/). Consent for publication Ethics approval and consent to participate

Declarations

Availability of data and materials

The dataset used and/or analyzed during the current study is available at the Open Science Framework (https://osf.io/4g8j/).

Funding

This collaborative meta-analysis was supported by the Swiss National Science Foundation and the Laura and John Arnold Foundation (grant supporting the post-doctoral fellowship at the Meta-Research Innovation Center at Stanford (METRICS), Stanford University). The funders had no role in the design of this collaborative meta-analysis, in the collection, analysis and interpretation of data, or in the report writing.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

During the conduct of the study, the following is reported: Dr. Berry reports being employee with ownership role at Berry Consultants (receives payments for statistical modeling and design of REMAP-CAP). Dr. Castillo reports grants from DOST-PCHRD. Dr. Daly reports grants from Medical Research Future Fund (Australian Govt) and RBWH. Dr. Denkinger reports grants from German Ministry for Education and Research. Dr. Dumagay reports grants from Philippine Council for Health Research and Development. Dr. Dunachie reports grants from UK Department of Health and Social Care, grants from UK National Institute of Health Research. Dr. Gaurian reports grants from Department of Science and Technology—Philippine Council for Health Research and Development. Dr. Gordon reports grants from NIH, grants from NIH Research Professorship (RP-2015-06-18), and non-financial support from NIH Clinical Research Network. Dr. Higgins reports grants from NIH/MRC and from the Minderoo Foundation. Dr. Hills reports grants from Health Research Council of New Zealand. Dr. Holm reports grants from Swedish Government Funds for Clinical Research (ALF). Dr. Janssen and Dr. Müller-Tidow report grants from the Federal Ministry of Education and Research in Germany (BMBF) to the RECOVER clinical trial. Dr. Krapp reports grants from Department of Foreign Affairs, Trade, and Development of Canada, grants from Fundación Telefónica del Perú. Dr. J. Lim reports grants from the Department of Science and Technology, Philippine Council for Health Research and Development. Dr. Lucero reports grants from Philippine Council for Health Research and Development. Dr. Manrique reports economic support from Grupo ISA Intercolombia for the project development of trial NCT04332835. Drs. McQuillen and Wood report grants from Medical Research Future Fund. Dr. McVerry reports grants from The Pittsburgh Foundation, Translational Breast Cancer Research Consortium, and from UPMC Learning While Doing Program. Mr. Mouncey reports grants from National Institute for Health Research and from the European Union FP7. PREPARE. Dr. Najdovski reports payment from RUL Leuven to Belgian Red Cross for supply of convalescent plasma. Dr. Nichol reports grants from Health Research Board of Ireland. Dr. D. Roberts reports grants from the National Institute for Health (UKRiDHSC COVID-19 Rapid Response Rolling Call—Grant Reference Number COV19-REPLACS) and the European Commission (SUPPORT-E #101015756). Dr. Rowan reports grants from the European Commission and from the UK National Institute for Health Research. Dr. Shankar-Hari reports grants from National Institute for Health Research, Health Economics and Technology Evaluation Team, University of Leeds, UK, from UKRI-National Institute for Health Research UK. Dr. Turgeon reports grants from Canadian Institutes of Health Research. Dr. Venkatesh reports grants from Baxter. Dr. Webb reports grants from National Health and Medical Research Council, grants from Minderoo Foundation. Dr. Zacharovski reports grants from EU Horizont 2020. The ASCOT trial team (Ors Bowen, Daly, Davis, Denholm, Hammond, Jha, L. Lim, McQuillen, Molton, Morphet, O’ Sullivan, Paterson, Perry, Price, Rees, Roberts, Sasadeusz, Snelling, Tong, Venkatesh, Wood) is funded by grants from from Royal Brisbane and Women’s Hospital Foundation, Pratt Foundation, Minderoo Foundation, BHP Foundation, Hospital Research Foundation, Macquarie Group Foundation, Health Research Council of New Zealand, Australian Partnership for Preparedness Research on Infectious Disease Emergencies (APPRISE), and the collection and supply of convalescent plasma was conducted within Lifeblood’s funding arrangements: The CONFIDENT trial was funded by the Belgian KCE (blood establishments received payment for the convalescent plasma supplied in the clinical trial). REMAP-CAP was supported in part by funding from UKRiDHSC COVID-19 Rapid Response Rolling Call (Grant Reference Number COV19-REPLACS). Collection of convalescent plasma for REMAP-CAP was funded by the Department of Health and Social Care, UK. The IRCT2020031014067361N1 trial was supported by the Ahvaz Jundishapur University of Medical Sciences (Grant No. RAJUMS.REC.1399.003, Dr. Pourlazdadeh). The PC-COVID-19 Group is supported by the Universidad del Rosario, IDCIBS, ISA Group and Suramericana (Colombia). Outside the submitted work, the following is reported: Dr. Afors reports postdoctoral grants from the Knut and Alice Wallenberg Foundation, Uppsala University, the Swedish Institute of Medicine, the Blanceflor Foundation, and the Sweden-America Foundation. Dr. Aomar reports personal fees from SOBI, GEDEON BICHTER, and GSK. Dr. Benfield reports grants from Novo Nordisk Foundation, Simonsen Foundation, Lundbeck Foundation, Kai Hansen Foundation, Erik and Susanna Olesen’s Charitable Fund; grants and personal fees from GS, Pfizer, Gilead, and personal fees from Boehringer Ingelheim, MSD, and Pentabase ApS. Dr. Estcourt reports an investigator on the RECOVERY trial. Dr. Gordon reports personal fees from GileadSmithKline, Bristol Myers Squibb, and 30 Respiratory. Dr. H. Jha reports grants and personal fees from Baxter Healthcare, personal fees from Astra Zeneca, grants from NephroPlus. Dr. Laterre reports personal fees from Adrenomed. Dr. McVerry reports grants from NIH/NHLBI and Bayer Pharmaceuticals, Inc. Dr. Mondragon reports financial activities outside the submitted work (employment at Johnson & Johnson). Dr. Perry reports another being employed at CSL and owning shares in CSL. Dr. Paterson reports involvement with ALLIANCE trial of COVID-19 treatments. Dr. J. Roberts reports other COVID-19 related trials (in different patient groups): tocilizumab in ICU patients; hydroxychloroquine dosing in ICU patients; planned study of remdesivir pharmacokinetics in patients during expanded access program; and in silico evaluation of remicetin dosing. Dr. Sasadeusz reports grants from various Pharma companies involved in Gilead Sciences, Abbvie, Merck and AstraZeneca. Dr. Zacharovski reports personal fees from Biotest AG, CSL Behing, GE Healthcare, and is President of the ESAC.
References

1. Barone P, Desimone RA. Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design. Transfusion. 2020;60(6):1123–7.
2. Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balthy H, Johan S, et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg Infect Dis. 2016;22(9):1554–61.
3. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw F-M, Lim WS, et al. Effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80–90.
4. Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, et al. Convalescent plasma in COVID-19: possible mechanisms of action. Autonimmun Rev. 2020;19(7):102554.
5. Klassen SA, Senefeld JT, Johnson PW, Carter RE, Wiggins CC, Shoham S, et al. The effect of convalescent plasma therapy on COVID-19 patient mortality: systematic review and meta-analysis. Mayo Clin Proc. 2021. https://www.mayoclinicproceedings.org/article/S0025-6196(21)00140-3/abstract. Accessed 27 Apr 2021.
6. Tanne JH. COVID-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ. 2020;60(368):m1366.
7. Budhai A, Wu AA, Hall L, Strauss D, Paradiso S, Alberigo J, et al. How did we rapidly implement a convalescent plasma program? Transfusion. 2020;60(7):1348–55.
8. Commissioner O of the FDA issues emergency use authorization for convalescent plasma as potential promising COVID-19 treatment, another achievement in administration's fight against pandemic. FDA. FDA; 2020. https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment. Accessed 14 Apr 2021.
9. Commissioner O of the FDA issues emergency use authorization for convalescent plasma as potential promising COVID-19 treatment, another achievement in administration's fight against pandemic. FDA. FDA; 2020. https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment. Accessed 27 Jan 2021.
10. European Commission. An EU programme of COVID-19 convalescent plasma collection and transfusion: Guidance on collection, testing, processing, storage, distribution and monitored use. https://ec.europa.eu/health/sites/health/files/blood_tissues_organ/docs/guidance_plasma_covid19_en.pdf. Accessed 27 Apr 2021.
11. European Commission. COVID-19 convalescent plasma collection. European Commission—European Commission. https://ec.europa.eu/commission/presscorner/detail/en/ip-21_50. Accessed 27 Apr 2021.

12. Simonovitch VA, Burgos-Pratt LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. N Engl J Med. 2020;383(15):151–7.

13. World Bank Country and Lending Groups—World Bank Data Help. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups. Accessed 14 Apr 2021.

14. Commissioner O of the. FDA In Brief: FDA updates emergency use authorization for COVID-19 convalescent plasma to reflect new data. FDA. 2021. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-updates-emergency-use-authorization-covid-19-convalescent-plasma-reflect-new-data. Accessed 14 Apr 2021.

15. Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA. 2020;324(5):1–11.

16. Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with COVID-19 disease. medRxiv. 2020.11.02.20224303.

17. Gharbharan A, Jordans CCE, Geurtsvankessel C, Hollander JG den, Karim AH, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Int J Epidemiol. 2020;39(6):2763–73.

18. Bajpai M, Kumar S, Maheshwari A, Chhabra K, Kale P, Gupta A, et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N Engl J Med. 2021;385(24):2344–54.

19. Avendano-Sola C, Ramos-Martinez A, Munee-Rubio E, Ruiz-Antoran B, Molina RM de, Torres F, et al. Convalescent plasma for COVID-19: a multi-center, randomized clinical trial. medRxiv. 2020;2020.08.26.20183444.

20. Ray Y, Paul SR, Bandopadhyay P, D’Rozario R, Sarif J, Lahiri A, et al. Randomized controlled trial (PLACID Trial). BMJ. 2020;371: m3939.

21. Janiaud P, Axfors C, Saccilotto R, Hemkens L. COVID-evidence: a living systematic review. Cochrane Database Syst Rev. 2020;11(2):CD002131.

22. Murphy M, Estcourt L, Grant-Casey J, Dzik S. International survey of trials of convalescent plasma to treat COVID-19 infection. Transfusion Med Rev. 2020;34(3):151–7.

23. COMET-Initiative. Core outcome set developers’ response to COVID-19 (7th July 2020). http://www.comet-initiative.org/Studies/Details/1538. Accessed 7 Oct 2020.

24. Group TRC, Horby PW, Estcourt L, Peto L, Emberson JR, Staplin N, et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv. 2020;2020.03.09.20237526.

25. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2013;346:f1486.

26. Sterne JA, Bello LM. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

27. Living overview of the evidence (LO-OVE). https://app.ilocovveidence.com/loves/5ef6fd869696004e0e4ac072701d1utm=epdb_en. Accessed 17 Dec 2020.

28. Higgins J, Sibbald R, Caubergs N, Hutton L, Michie P, et al. Controlling the impact of risk bias in randomised trials. BMJ. 2019;366:14898.

29. Higgins JA, Savovic J, Page MJ, Elbers RG, Henry JA, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2017;358:j4974.

30. Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane handbook for systematic reviews of interventions. www.training.cochrane.org/handbook. Accessed 14 Apr 2021.

31. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.

32. Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, et al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods. 2016;7(1):55–79.

33. Food and Drug Administration. Convalescent plasma EUA letter of authorization, March 9, 2021. https://www.fda.gov/media/141477/download.
Abelardo Zuhiga RA, Coca SM, Abelardo GF, González-Villoria RAM. Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis. Ther Adv Respir Dis. 2021;15:17534662211007214.

Abubakar AR, Sani IH, Godman B, Kumar S, Islam S, Jahan I, et al. Systematic review on the therapeutic options for COVID-19: clinical evidence of drug efficacy and implications. Infect Drug Resist. 2020;13:4673–95.

Bakhtawar N, Usman M, Khan MMU. Convalescent plasma therapy and its effects on COVID-19 patient outcomes: a systematic review of current literature. Cureus. 2020;12(8):e9535.

Fabricius MM, Dandachi D. COVID-19 convalescent plasma: from donation to treatment—a systematic review and single center experience. Mo Med. 2021;118(1):74–80.

Kim MS, An MH, Kim WJ, Hwang TH. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: a systematic review and network meta-analysis. PLoS Med. 2020;17(12):e1003501.

Meher BR, Padhy BM, Das S, Mohanty RR, Agrawal K. Effectiveness of convalescent plasma therapy in the treatment of moderate to severe COVID-19 patients: a systematic review and meta-analysis. J Assoc Phys India. 2020;68(12):35–43.

Peng HT, Rhind SG, Beckett A. Convalescent plasma for the prevention and treatment of COVID-19: a systematic review and quantitative analysis. JMIR Public Health Surveill. 2021;7(4):e25500.

Rajendran K, Krishnasamy N, Rangarajan J, Rathanam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: a systematic review. J Med Virol. 2020;92(9):1475–83.

Sarkar S, Soni KD, Khanna P. Convalescent plasma is a clutch at straws in COVID-19: a systematic review and meta-analysis. J Med Virol. 2021;93(2):1111–8.

Talaei H, Hosseini SM, Nazari M, Fakhrizadeh A, Vatanpour H, et al. Is there any potential management against COVID-19? A systematic review and meta-analysis. Cureus. 2020;12(8):765–77.

Wang M, Wu T, Zuo Z, You Y, Yang X, Pan L, et al. Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis. BMJ Support Palliat Care. 2021;11(1):45–52.

Wenjing L, Yuanzheng F, Li J-Y, Tang LV, Yu H. Safety and efficacy of convalescent plasma therapy in severely and critically ill patients with COVID-19: a systematic review with meta-analysis. Aging (Albany NY). 2020;13(1):1496–509.

Zhang X, Xi L, Pang F, Du Y, Yuan Q, Shi M, et al. Convalescent plasma in the treatment of severe COVID-19: a systematic review and meta-analysis. Iran J Public Health. 2020;49(11):2022–31.

Janiaud P, Axfors C, Schmitt AM, Gloy E, Ebhartm F, Hepprich M, et al. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA. 2021. https://doi.org/10.1001/jama.2021.2747.

Prasad M, Seth T, Elavarasi A. Efficacy and safety of convalescent plasma for COVID-19: a systematic review and meta-analysis. Indian J Hematol Blood Transfus. 2021;16:1–19.

Aviani JK, Halim D, Soeroto AY, Achmad TH, Djauwanto T. Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID-19) treatment: a systematic review and meta-analysis based on recent studies and previous respiratory pandemics. Rev Med Virol. 2021. https://doi.org/10.1002/rmv.2225.

Vegivinti CTR, Pederson JM, Saravu K, Gupta N, Evansson KW, Kamrowski S, et al. Efficacy of convalescent plasma therapy for COVID-19: a systematic review and meta-analysis. J Clin Apher. 2021. https://doi.org/10.1002/jca.21881.

Wang Y, Luo D, Dai R, Lv X, Yuan S, Zhang Y, et al. Convalescent plasma may be a possible treatment for COVID-19: a systematic review. Int Immunopharmacol. 2021;91:107262.

Rasheed AM, Fataf DF, Hashim HA, Maulood MF, Kabab KK, Almusawi YA, et al. The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. Infez Med. 2020;28(3):357–66.

Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252–60.

Schmucker CM, Blümle A, Schell LK, Schwarzer G, Oeller P, Cabrera L, et al. Systematic review finds that study data not published in full text articles have unclear impact on meta-analyses results in medical research. PLoS ONE. 2017;12(4):e0176210.

Salcioho Hillel M, Grabitz P, Pugh-Jones M, Strech D, DeVito NJ. Results availability and timeliness of registered COVID-19 clinical trials: a cross-sectional study. medRxiv. 2021;2021.04.07.21255071.